Is It Time to Dump Your Shares of Eli Lilly?

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are both highly respected pharmaceutical companies. However, their stock prices have traveled shockingly different paths over the past year or so, with Eli Lilly on the rise and Novo Nordisk falling sharply. Both price moves are the result of GLP-1 drugs. Has the good news played out for Eli Lilly?Novo Nordisk was the first company to introduce GLP-1 drugs. This is a new category of drugs that helps people lose material amounts of weight very quickly. As long as patients continue to use the drug, the weight remains off. The drugs, currently delivered by needle, have been hailed as something of a miracle, especially for people who have had a hard time controlling their weight through diet and exercise alone.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool